OR4C6 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lidocaine | 137-58-6 | sc-204056 sc-204056A | 50 mg 1 g | $50.00 $128.00 | ||
Lidocaine is a sodium channel blocker that impedes neuronal action potential propagation. If OR4C6 is a neuronal protein that relies on action potential-mediated signaling for its activity, lidocaine would inhibit OR4C6 by preventing the initiation or propagation of action potentials. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor and could inhibit OR4C6 if OR4C6 is involved in pathways regulated by mTOR, such as growth, proliferation, and survival pathways. | ||||||
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
Haloperidol is a dopamine receptor antagonist that can inhibit dopamine signaling. If OR4C6 is part of a dopamine-dependent signaling pathway, haloperidol would inhibit OR4C6 activity by blocking dopamine receptors. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Verapamil is an L-type calcium channel blocker. It inhibits the influx of calcium ions, which are vital for various cellular processes. If OR4C6 requires calcium-mediated signaling for its activity, verapamil would inhibit it by blocking these channels. | ||||||
Dantrolene | 7261-97-4 | sc-500165 | 25 mg | $350.00 | 7 | |
Dantrolene inhibits ryanodine receptors on the sarcoplasmic reticulum, which are involved in calcium release. If OR4C6 is activated by intracellular calcium release, dantrolene would inhibit OR4C6 by reducing calcium availability. | ||||||
Amiloride • HCl | 2016-88-8 | sc-3578 sc-3578A | 25 mg 100 mg | $22.00 $56.00 | 6 | |
Amiloride is a diuretic that acts as a sodium-proton exchanger blocker and also inhibits certain sodium channels. Its action on sodium homeostasis could inhibit OR4C6 if OR4C6 activity is sodium-dependent. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $127.00 | 18 | |
Losartan is an angiotensin II receptor blocker, which would inhibit OR4C6 if OR4C6 activity is modulated by angiotensin II receptor signaling pathways. | ||||||
Diazoxide | 364-98-7 | sc-200980 | 1 g | $300.00 | 5 | |
Diazoxide opens ATP-sensitive potassium channels, leading to membrane hyperpolarization. If OR4C6 activity is linked to membrane potential or potassium channel activity, diazoxide would inhibit OR4C6 by stabilizing the membrane in a hyperpolarized state. | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $80.00 $326.00 | 1 | |
Ondansetron is a selective serotonin 5-HT3 receptor antagonist. If OR4C6 is involved in serotonin signaling pathways, ondansetron would lead to OR4C6 inhibition by blocking these receptors. | ||||||